Literature DB >> 16211716

Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis.

Einar Björnsson1, Anna Cederborg, Anders Akvist, Magnus Simren, Per-Ove Stotzer, Ingvar Bjarnason.   

Abstract

OBJECTIVE: Animal studies show that small intestinal bacterial overgrowth and infusion of bacterial antigens into portal blood cause hepatic histological changes similar to those seen in primary sclerosing cholangitis in man. It has been suggested that aa similar mechanism involving bacterial overgrowth with increased small-bowel permeability may play a pathogenic role in patients with primary sclerosing cholangitis (13 M, 9 F, median age 37 years, range 21-74 years), 19 of whom (83%) had quiescent inflammatory bowel disease, were included in the study along with 18 healthy volunteers (9 F, ( M, median age 36 years, range 23-80 years). Small-bowel bacterial overgrowth was defined as the presence of colonic flora>10(5) colony-forming units (cfu)/ml from duodenal aspirations. Small-bowel intestinal permeability was assessed as the differential urinary excretion of lactulose/L-rhamnose.
RESULTS: Bacterial overgrowth was evident in one patient with primary sclerosing cholangitis (4.5%) (Enterobacter) and in none of the controls. Intestinal permeability in patients with primary sclerosing cholangitis (0.034 (0.026-0.041) (median, interquartile range (IQR)) did not differ significantly from that of the controls (0.033 (0.025-0.041).
CONCLUSIONS: Small intestinal bacterial overgrowth and increased intestinal permeability does not seem to play an important pathogenic role in patients with primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211716     DOI: 10.1080/00365520510023288

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  17 in total

1.  Cutting edge issues in primary sclerosing cholangitis.

Authors:  Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 2.  Leaky gut: mechanisms, measurement and clinical implications in humans.

Authors:  Michael Camilleri
Journal:  Gut       Date:  2019-05-10       Impact factor: 23.059

Review 3.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

Review 4.  Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease--a comprehensive review.

Authors:  Luca Maroni; Stan F J van de Graaf; Simon D Hohenester; Ronald P J Oude Elferink; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

Review 6.  A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis.

Authors:  Mohammed Saadi; Christine Yu; Mohamed O Othman
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

7.  Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis.

Authors:  Christian Rupp; Konrad Alexander Bode; Fadi Chahoud; Andreas Wannhoff; Kilian Friedrich; Karl-Heinz Weiss; Peter Sauer; Wolfgang Stremmel; Daniel Nils Gotthardt
Journal:  BMC Infect Dis       Date:  2014-10-23       Impact factor: 3.090

Review 8.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

Review 9.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

Review 10.  The gut microbiota and host health: a new clinical frontier.

Authors:  Julian R Marchesi; David H Adams; Francesca Fava; Gerben D A Hermes; Gideon M Hirschfield; Georgina Hold; Mohammed Nabil Quraishi; James Kinross; Hauke Smidt; Kieran M Tuohy; Linda V Thomas; Erwin G Zoetendal; Ailsa Hart
Journal:  Gut       Date:  2015-09-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.